Silo pharma achieves milestone - partner zylo therapeutics receive dea approval to advance silos time released ketamine technology

Englewood cliffs nj, oct. 07, 2021 (globe newswire) -- silo pharma, inc. (otcqb: silo) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner zylo therapeutics received approval from the dea to advance the development of their z-pod technology in combination with ketamine.
SILO Ratings Summary
SILO Quant Ranking